See analyst estimates and all valuation multiples for Nutraceuticals & Cosmeceuticals
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $29.1B | 1.9x | 7.8x | |
| $18.4B | 16.0x | 49.1x | |
| $14.6B | 10.2x | 32.2x | |
| $11.1B | 3.3x | 7.9x | |
| $7.4B | 4.7x | 23.7x | |
| $6.4B | 8.4x | 30.7x | |
| $3.6B | 1.7x | 10.2x | |
| $3.3B | 2.4x | 8.8x | |
| $3.0B | 1.5x | 9.7x | |
| $2.7B | 7.1x | 16.2x | |
| $2.0B | 1.9x | 7.5x | |
| $1.7B | n/a | n/a | |
| $1.4B | 4.8x | 9.4x | |
| $1.3B | 2.2x | 11.5x | |
| $1.2B | 7.1x | 25.3x | |
| $1.1B | n/a | n/a | |
| $998M | 4.6x | 16.8x | |
| $971M | 7.6x | 28.5x | |
| $905M | 3.8x | 9.1x | |
| $867M | n/a | n/a | |
| $866M | 1.9x | 9.1x | |
| $681M | 4.4x | 17.4x | |
| $635M | n/a | n/a | |
| $485M | n/a | n/a | |
| $442M | 3.5x | 21.8x | |
| $395M | n/a | n/a | |
| $334M | n/a | n/a | |
| $188M | 2.9x | n/a | |
| $185M | 2.2x | 13.1x | |
| $143M | 2.1x | 13.2x | |
| $85.3M | n/a | n/a | |
| $75.1M | n/a | n/a | |
| $70.5M | 4.6x | 47.4x | |
| $44.6M | 1.3x | 4.3x | |
| $29.3M | n/a | n/a | |
| $26.2M | n/a | n/a | |
| $25.9M | 1.4x | -15.3x | |
| $24.4M | n/a | n/a | |
| $10.1M | 8.1x | -1.0x | |
| $8.2M | n/a | n/a | |
| $6.7M | n/a | n/a | |
| $4.7M | n/a | n/a | |
| $0.3M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Nutraceuticals & Cosmeceuticals